A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

Pokaži ostale verzije (1)

Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐...

Cijeli opis

Bibliografski detalji
Glavni autori: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, Bart van den Berg van Saparoea, H., Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Riley Richardson, M., Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory, Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
Format: Online Članak Tekst
Jezik:English
Izdano: John Wiley and Sons Inc. 2022
Teme:
Research Articles
Online pristup:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

Slična djela